Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model
作者： Xiaoyan Su , Wei Xu , Ran Guan , Yunhao Wang , Jie Wu
DOI: 10.1016/J.INTIMP.2016.05.005
关键词:
摘要: We previously demonstrated that the antineoplastic agent docetaxel enhanced immune response to an influenza vaccine. This study evaluated adjuvant effect of (DOC) on therapeutic efficacy HPV16 L2E6E7 fusion protein (HPV-LFP) in mice inoculated with TC-1 cells. The results significantly HPV-LFP cell-induced tumors mice. injection combination tumor-bearing reduced tumor volume and weight, a greater percent survival was detected than treated alone. inhibition associated increased serum antigen-specific IgG isotypes, activated CTLs, IFN-γ-secreting T cells, decreased Treg cells IL-10-secreting spleen. In addition, down-regulation IL-10, VEGF STAT3, up-regulation IFN-γ microenvironment may also important contributing factors antitumor effect. It be valuable use DOC-containing water dilute powder before patients because its excellent solubility water.
sci-hub.se 参考文章(41)
Andreas M Kaufmann, Malcolm Adams, Julian K Hickling, John St C Roberts, Uwe Wagner, Jantien Wanders, Karlijn Kroon, Volkmar Nuessler, Jennifer Gillard, Elaine M Rankin, Thomas Bauknecht, Heinz Zwierzina, Simon N Stacey, Christopher M Boswell, Achim Schneider, Harald Sommer, Peter L Stern, Henry C Kitchener, Toli S Onon, Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clinical Cancer Research. ,vol. 8, pp. 3676- 3685 ,(2002)
Samantha Jayne Hibbitts, TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. Current Opinion in Molecular Therapeutics. ,vol. 12, pp. 598- 606 ,(2010)
Hyam I. Levitsky, J. Thomas August, Tzyy Choou Wu, Kevin F. Staveley-O'Carroll, Frank G. Guarnieri, Ken Yu Lin, Drew M. Pardoll, Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen Cancer Research. ,vol. 56, pp. 21- 26 ,(1996)
Emma J. Crosbie, Henry C. Kitchener, Human papillomavirus in cervical screening and vaccination. Clinical Science. ,vol. 110, pp. 543- 552 ,(2006) , 10.1042/CS20050230
Paola Pisani, D. Maxwell Parkin, Freddie Bray, Jacques Ferlay, Estimates of the worldwide mortality from 25 cancers in 1990. International Journal of Cancer. ,vol. 83, pp. 18- 29 ,(1999) , 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M
A de Jong, T O’Neill, A.Y Khan, K.M.C Kwappenberg, S.E Chisholm, N.R Whittle, J.A Dobson, L.C Jack, J St Clair Roberts, R Offringa, S.H van der Burg, J.K Hickling, Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine Vaccine. ,vol. 20, pp. 3456- 3464 ,(2002) , 10.1016/S0264-410X(02)00350-X
A Kobayashi, V Weinberg, T Darragh, K Smith-McCune, Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunology. ,vol. 1, pp. 412- 420 ,(2008) , 10.1038/MI.2008.33
Weiping Zou, Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews Cancer. ,vol. 5, pp. 263- 274 ,(2005) , 10.1038/NRC1586
Suzanne M. Garland, Jennifer S. Smith, Human papillomavirus vaccines: current status and future prospects. Drugs. ,vol. 70, pp. 1079- 1098 ,(2010) , 10.2165/10898580-000000000-00000
Azam Bolhassani, Elham Mohit, Sima Rafati Rafati, Different spectra of therapeutic vaccine development against HPV infections. Human Vaccines. ,vol. 5, pp. 671- 689 ,(2009) , 10.4161/HV.5.10.9370